|1.||Luszczki, Jarogniew J: 13 articles (03/2015 - 10/2003)|
|2.||Czuczwar, Stanisław J: 9 articles (07/2015 - 05/2003)|
|3.||Schousboe, Arne: 5 articles (02/2015 - 08/2002)|
|4.||Marson, Anthony G: 5 articles (01/2014 - 01/2009)|
|5.||Kälviäinen, Reetta: 5 articles (11/2010 - 12/2005)|
|6.||Perucca, E: 5 articles (12/2001 - 05/2000)|
|7.||Patsalos, Philip N: 4 articles (12/2013 - 03/2009)|
|8.||Krogsgaard-Larsen, Povl: 4 articles (07/2011 - 08/2002)|
|9.||White, H Steve: 4 articles (07/2011 - 08/2002)|
|10.||Czuczwar, Stanislaw J: 4 articles (08/2009 - 04/2004)|
03/01/1998 - "The percentage of patients achieving an increase of at least 50% in the proportion of days free of all partial seizures was significantly greater in the tiagabine group compared to placebo (14 versus 4%, P<0.01). "
04/01/1994 - "Systemically administered tiagabine also produced a significant reduction in seizure severity in the GEPR-9. "
03/01/1998 - "The present study shows that tiagabine, at a dose of 10 mg administered three-times daily, which is at the lower end of the usual recommended dose range (30-50 mg/day, tiagabine base), is generally well tolerated and demonstrates efficacy for the treatment of refractory partial seizures."
07/01/1997 - "Tiagabine is a novel antiepileptic drug which has clinical efficacy against complex refractory and myoclonic seizures. "
07/01/1997 - "tiagabine) in that enhanced efficacy against MES and reduced efficacy against kindled seizures is observed. "
02/15/2012 - "Tiagabine hydrochloride monohydrate drug substance (TGB) is an antiepileptic agent effective in the treatment of seizure disorders. "
10/01/2004 - "This observational study has demonstrated tiagabine to be effective and safe in patients with refractory epilepsy."
01/01/2000 - "Tiagabine appeared to be an effective and safe drug in resistant epilepsy in children below 12 years of age."
12/01/2000 - "This 4-month, single-blind study evaluated the tolerability, safety and preliminary efficacy of ascending doses (0.25-1.5 mg/kg/day) of tiagabine add-on therapy in 52 children over the age of 2 years with different syndromes of refractory epilepsy. "
01/01/2013 - "Following the period of a great enthusiasm as to the use of tiagabine, it was put aside, though unfairly, according to the author's own studies as well as the reports in current literature, it still has its place in the treatment of drug-resistant epilepsy."
|3.||Partial Epilepsies (Epilepsy, Partial)
08/01/1999 - "Tiagabine (TGB) is effective in patients with focal epilepsies. "
03/01/1998 - "Thus, tiagabine is a new antiepileptic agent with a novel mechanism of action, which has demonstrated efficacy in the adjunctive treatment of patients with refractory partial epilepsy. "
03/01/2005 - "The aim of the current study was to review the efficacy of tiagabine (TGB) as add-on therapy in patients with drug-resistant focal epilepsy under normal daily clinical practice, and try to identify those who had improvement. "
01/01/1997 - "A dose-response trial that tested the efficacy of tiagabine monotherapy in patients with refractory partial epilepsy was uninformative. "
07/01/2008 - "GABI-balance--a non-interventional observational study on the effectiveness of tiagabine in add-on therapy in partial epilepsy."
12/01/2001 - "Pain symptoms and quantitative sensory test results improved with treatment, especially at low doses of tiagabine (4-8 mg). "
12/01/2001 - "Low doses (4-8 mg) of tiagabine reduced pain symptoms by 16-38%, improving surface pain (37.5%), skin sensitivity (32.8%), burning (38.6%), cold (25.4%) and pain sharpness (29%; p <0.03). "
12/01/2001 - "Weeks 1-4: Dose of tiagabine was increased weekly by 4 mg orally up to 16 mg in week 4. Quantitative sensory testing for vibration, cooling, and heat-pain, and quantitative sudomotor axon reflex test (QSART) were done at week 0 and week 4. The McGill Pain Questionnaire was administered weekly. "
01/01/2005 - "Tiagabine may reduce bruxism and associated temporomandibular joint pain."
08/01/2009 - "If the results from this study could be extrapolated to clinical settings, the combination of tiagabine with gabapentin might be beneficial in the pain relief in humans."
|5.||Bipolar Disorder (Mania)
01/01/2011 - "The main outcomes to be assessed were:(1) the efficacy of tiagabine treatment in preventing or attenuating further episodes of bipolar disorder, including its efficacy in rapid cycling disorder; (2) the acceptability of tiagabine treatment to participants; (3) the prevalence of side effects; and (4) mortality, if any, on tiagabine treatment.Outcomes"
01/01/2002 - "We reviewed the available literature on the efficacy of a novel anticonvulsant, Tiagabine (TGB), in the treatment of bipolar disorder. "
09/01/2002 - "Three published studies have addressed the use of tiagabine for bipolar disorder (BPD); two described positive results and one negative results. "
10/01/2002 - "Open add-on tiagabine for treatment-refractory patients with bipolar disorder demonstrated limited efficacy with the majority of patients showing no change or worsening of clinical symptoms. "
01/01/2012 - "We found no randomised controlled trials of tiagabine in the treatment of acute episodes of bipolar disorder. "
|6.||gamma-Aminobutyric Acid (GABA)
|8.||Anticonvulsants (Antiepileptic Drugs)
|1.||Vagus Nerve Stimulation
|3.||Psychology Biofeedback (Biofeedback)